Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma.
about
Molecular pathology of prostate cancerCOX2 genetic variation, NSAIDs, and advanced prostate cancer riskArachidonic acid metabolism in human prostate cancerDecrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue.COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial.Sex hormones induce direct epithelial and inflammation-mediated oxidative/nitrosative stress that favors prostatic carcinogenesis in the noble rat.Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers.Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independenceProstate cancer and inflammation: the evidence.Vitamin D metabolism and action in the prostate: implications for health and disease.Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination SurveyUrsolic acid inhibits the initiation, progression of prostate cancer and prolongs the survival of TRAMP mice by modulating pro-inflammatory pathwaysProstate-associated gene 4 (PAGE4) protects cells against stress by elevating p21 and suppressing reactive oxygen species productionAssociation of the innate immunity and inflammation pathway with advanced prostate cancer risk.Evidence for field cancerization of the prostate.The anti-cancer and anti-inflammatory actions of 1,25(OH)₂D₃Migrating with myosin VI.Anti-inflammatory drugs, antioxidants, and prostate cancer prevention.α(V)β(6) integrin expression is induced in the POET and Pten(pc-/-) mouse models of prostatic inflammation and prostatic adenocarcinoma.Markers of field cancerization: proposed clinical applications in prostate biopsiesAspirin but not ibuprofen use is associated with reduced risk of prostate cancer: a PLCO studyFalse cell lines: The problem and a solutionInflammation in prostate carcinogenesis.A mechanism underlying the effects of polyunsaturated fatty acids on breast cancer.COX-2 expression and function in the hyperalgesic response to paw inflammation in mice.Non-Steroidal Anti-Inflammatory Drugs, Variation in Inflammatory Genes, and Aggressive Prostate Cancer.Green tea and prostate cancer: from bench to clinic.Microsomal prostaglandin E synthase 1 determines tumor growth in vivo of prostate and lung cancer cellsRoles of Eicosanoids in Prostate Cancer.The role of vitamin D in cancer prevention and treatment.The role of vitamin D in cancer prevention and treatment.The diet as a cause of human prostate cancer.IL-17 Expression by macrophages is associated with proliferative inflammatory atrophy lesions in prostate cancer patients.Inhibition of prostaglandin synthesis and actions by genistein in human prostate cancer cells and by soy isoflavones in prostate cancer patients.Inflammatory suppressive effect of prostate cancer cells with prolonged exposure to transforming growth factor β on macrophage-differentiated cells via downregulation of prostaglandin E2Mechanism of growth inhibition of prostate cancer xenografts by valproic acid.Does valproic acid induce neuroendocrine differentiation in prostate cancer?Regulation of Cox-2 by cyclic AMP response element binding protein in prostate cancer: potential role for nexrutine.Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy.Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-captur
P2860
Q24672410-B4BC0A8D-D543-4ACB-B296-CCCA5C668C73Q28217972-26748FD4-846C-4362-A1A4-C69011EBE7FBQ28273154-1CE20067-7489-4824-BD94-C29B988BD447Q31074064-5F721047-32A9-4D2A-8935-0903D3E65B35Q31130013-156764DB-86BE-4562-A2D3-5EDDE2536F5FQ33295021-2F496331-0CC4-4E74-831D-219C158DB1B7Q33561179-1F9635B3-5E32-44D4-B9AA-DBA9A1CABDC9Q33579568-804FF1A1-B531-4134-9925-A2CCA41F7B37Q33642321-60AA6124-7686-4D0A-BE94-8EB6AE073ECCQ34027269-328E9406-6030-4707-A254-08DA771A193BQ34131771-659EE400-509E-415A-8101-209179B4F728Q34199851-FE814D01-7461-44F3-85FE-D24DDF289592Q34448124-01986EE8-34F4-4367-9844-D5E9A839517FQ34525515-2361796E-CDB3-49F6-A944-A69CC0649D24Q34982560-5AD40302-905D-44D3-93D7-F8F7F1070E4AQ35188826-73DE4AF8-2700-43ED-BE03-43758451A264Q35607346-C1CA1F97-8188-451A-A8E2-D95783ACD38AQ35775751-98B1B733-460B-4840-8905-110723DADEF6Q35964178-58740226-9CB6-43DF-BDA3-37EE841B2F6CQ35991148-EFE56F97-B231-422B-B29E-C229ACC31AB4Q36075269-9CE38DDF-2847-4FB9-B029-C6F91C95AA4CQ36296670-89A8E526-2EFA-4D9A-97E2-D34F99024571Q36554784-E44021B3-0F58-4216-A1E2-4750DA4D5C8FQ36613639-D46D7BF6-24D7-4574-A69D-9E4656C88C4BQ37042403-FB643C2C-A528-403D-A103-BB6E737AD619Q37155271-24232F67-4900-4F84-87FA-0BA3C75BB2ADQ37308282-FAF6E93F-A0C8-4EE4-A31E-2713673F00DEQ37401875-D9B052F2-9831-435F-ACA6-6DF0955C7EE2Q37592857-9DD3DB5A-89C1-4A46-B654-AC9DEB0417C0Q37761548-353056CF-7941-4B75-BE9C-BD239172C977Q38004753-890D02BE-C464-40F4-9CE3-A6B5C4155302Q38151527-621225AB-C055-4676-BD06-B04F80274A16Q38256438-227EC1A9-C8BF-4065-B4DC-F94AFCA01221Q38762796-3EDA8CB8-14BA-4328-BBF8-AC6D4913F915Q38958274-87DAF1D9-CBDF-4A22-9977-D68D9DEE60B1Q39254228-A244F998-C63F-4AAD-815F-22D534DD8139Q39638991-C80E1AF5-4449-49CA-80F1-53989370AF47Q40046885-D9A256F4-5AAD-4FA0-A797-D24696F80B33Q41977380-4147EEE7-0F0D-43F0-BD88-16E658B8D4D1Q42047685-56386FBE-1A5B-403B-8273-5956B80AC3E7
P2860
Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Cyclooxygenase-2 is up-regulat ...... but not in prostate carcinoma.
@en
Cyclooxygenase-2 is up-regulat ...... but not in prostate carcinoma.
@nl
type
label
Cyclooxygenase-2 is up-regulat ...... but not in prostate carcinoma.
@en
Cyclooxygenase-2 is up-regulat ...... but not in prostate carcinoma.
@nl
prefLabel
Cyclooxygenase-2 is up-regulat ...... but not in prostate carcinoma.
@en
Cyclooxygenase-2 is up-regulat ...... but not in prostate carcinoma.
@nl
P2093
P1433
P1476
Cyclooxygenase-2 is up-regulat ...... but not in prostate carcinoma
@en
P2093
De Marzo AM
Sauvageot J
P304
P407
P577
2001-12-01T00:00:00Z